Regeneron Pharmaceuticals (REGN) said Tuesday it will boost its American manufacturing footprint by partnering with Fujifilm Diosynth Biotechnologies to produce biologics at a new North Carolina site.
The long-term agreement grants Regeneron access to Fujifilm's recently built biopharma facility in Holly Springs, the company said, nearly doubling its current large-scale manufacturing volume in the US.
The project, set to begin with an immediate technology transfer, represents a total investment of more than $3 billion over ten years, Regeneron said.
Regeneron said it is advancing multiple initiatives in New York, including a $3.6 billion expansion in Tarrytown, a fill-and-finish plant in Rensselaer, and a newly acquired property in Saratoga Springs for future growth.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。